Liraglutide
SAXAPCOS
Novo Nordisk · Phase 3 · Completed · Enrollment 88
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Liraglutide Pen Injector (Saxenda) | n/r | n/r | n/r | n/r |
| Placebo liraglutide pen injector | n/r | n/r | n/r | n/r |
Not shown
- Liraglutide Pen Injector (Saxenda): endpoint not reported
- Placebo liraglutide pen injector: endpoint not reported